JPH0378364B2 - - Google Patents

Info

Publication number: JPH0378364B2
Authority: JP; Japan
Prior art keywords: dogs; calcium; dobesylate; lymph; calcium dobesylate
Prior art date: 1981-12-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP57225752A

Other languages

English (en)

Japanese (ja)

Other versions

JPS58116416A (ja

Inventor

Do Kuurutan Arufure

Shurutesu Adorian

Esutebuusoreru Joze

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

RABO OMU SA

Original Assignee

RABO OMU SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-12-23

Filing date

1982-12-22

Publication date

1991-12-13

1982-12-22 Application filed by RABO OMU SA filed Critical RABO OMU SA

1983-07-11 Publication of JPS58116416A publication Critical patent/JPS58116416A/ja

1991-12-13 Publication of JPH0378364B2 publication Critical patent/JPH0378364B2/ja

Status Granted legal-status Critical Current

Links

208000010125 myocardial infarction Diseases 0.000 claims description 5
150000001875 compounds Chemical class 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 3
229940124597 therapeutic agent Drugs 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 1
241000282472 Canis lupus familiaris Species 0.000 description 13
239000011575 calcium Substances 0.000 description 13
229910052791 calcium Inorganic materials 0.000 description 13
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 12
210000002751 lymph Anatomy 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
206010011086 Coronary artery occlusion Diseases 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108010003272 Hyaluronate lyase Proteins 0.000 description 2
102000001974 Hyaluronidases Human genes 0.000 description 2
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
239000000006 Nitroglycerin Substances 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
206010003119 arrhythmia Diseases 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
229960002773 hyaluronidase Drugs 0.000 description 2
238000011221 initial treatment Methods 0.000 description 2
238000002587 lymphangiography Methods 0.000 description 2
210000001365 lymphatic vessel Anatomy 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
CTLTUPWEUCZSIP-UHFFFAOYSA-N 1,4-dihydroxycyclohexa-2,4-diene-1-sulfonic acid Chemical compound OC1=CCC(O)(S(O)(=O)=O)C=C1 CTLTUPWEUCZSIP-UHFFFAOYSA-N 0.000 description 1
108010082126 Alanine transaminase Proteins 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
101100462505 Mus musculus Pik3c2a gene Proteins 0.000 description 1
206010064966 Myocardial oedema Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
150000001669 calcium Chemical class 0.000 description 1
QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical compound [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000004087 circulation Effects 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
-1 for example Chemical class 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000032630 lymph circulation Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000000034 method Methods 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
230000003680 myocardial damage Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP22575282A 1981-12-23 1982-12-22 心筋梗塞治療剤 Granted JPS58116416A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33367181A	1981-12-23	1981-12-23
US333671		1994-11-03

Publications (2)

Publication Number	Publication Date
JPS58116416A JPS58116416A (ja)	1983-07-11
JPH0378364B2 true JPH0378364B2 (fr)	1991-12-13

Family

ID=23303775

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP22575282A Granted JPS58116416A (ja)	1981-12-23	1982-12-22	心筋梗塞治療剤

Country Status (2)

Country	Link
JP (1)	JPS58116416A (fr)
IT (1)	IT1212555B (fr)

1982
- 1982-12-21 IT IT8249714A patent/IT1212555B/it active
- 1982-12-22 JP JP22575282A patent/JPS58116416A/ja active Granted

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEM.ABSTR=1972 *

Also Published As

Publication number	Publication date
IT1212555B (it)	1989-11-30
IT8249714A0 (it)	1982-12-21
JPS58116416A (ja)	1983-07-11

Similar Documents

Publication	Publication Date	Title
EP1744739B1 (fr)	2010-03-31	Utilisation de treprostinile pour traiter des ulceres diabetiques neuropathiques du pied
Fredlund et al.	1983	Long QT interval and ventricular tachycardia of “torsade de pointe” type in hypothyroidism
Rowland et al.	1980	Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias.
Gaffney et al.	1963	Study of the relationship between the neurotransmitter store and adrenergic nerve block induced by reserpine and guanethidine
KR20110026422A (ko)	2011-03-15	영구적 심방 세동의 예방을 위한 드로네다론
JPH0717502B2 (ja)	1995-03-01	狭心症治療用バクロフェン
Gould et al.	1969	Treatment of cardiac arrhythmias with phentolamine
KR20110026421A (ko)	2011-03-15	심장율동전환의 예방을 위한 드로네다론
JPH0378364B2 (fr)	1991-12-13
Hooqenhuvze et al.	1982	Acute effects of intravenous amiodarone in patients with complex ventricular dysrhythmias
Kim et al.	1982	Large dose sublingual nitroglycerin in acute myocardial infarction: relief of chest pain and reduction of Q wave evolution
CN115634243A (zh)	2023-01-24	双黄连治疗乌头碱中毒导致的心律失常药物中的应用
JP2769217B2 (ja)	1998-06-25	心臓状態の処置のためのプロパフェノン及びキニジンの持効性組成物
Waldman	1945	The treatment of angina pectoris with testosterone propionate
RU1812991C (ru)	1993-04-30	Способ лечени стенокардии напр жени
Conrad et al.	1968	Transvenous pacing in two patients with repetitive ventricular arrhythmias
RU2320328C2 (ru)	2008-03-27	Способ лечения персистирующей формы фибрилляции предсердий
Shector et al.	1955	Ventricular arrhythmia induced by methoxamine hydrochloride
Lüderitz	1998	Historical perspectives on cardioversion and defibrillation
Hood Jr et al.	1968	Treatment of refractory ventricular tachysystole with hyperbaric oxygenation
SU1007674A1 (ru)	1983-03-30	Способ лечени экстрасистолической аритмии у детей
Dear	1970	Spontaneous reversion of complete A‐V block to sinus rhythm in the dog
Mah	1969	Cardioversion in the treatment of atrial flutter
McAllen	1971	Experiences of coronary intensive care in a district hospital.
Raggi et al.	1995	Myocardial Infarction and Dynamic Left Ventricular Outflow Obstruction Induced by Bronchodilator Therapy